Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 7/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530548 | 0.88 | SCN1A (0.39) | SCN1ASCN8AKCNH2HRH3POLB | |
| SCHEMBL5532983 | 0.88 | GRM2 (0.41) | SCN1ASCN8AKCNH2HRH3SLC2A1 | |
| SCHEMBL8236599 | 0.87 | POLB (0.38) | SCN1ASCN8APOLBL3MBTL1 | |
| SCHEMBL5529449 | 0.87 | SOS1 (0.41) | SCN1ASCN8AKCNH2HRH3SLC2A1 | |
| SCHEMBL5530620 | 0.86 | KCNH2 (0.41) | KCNH2HRH3SLC2A1RBP4TTR | |
| SCHEMBL5530042 | 0.85 | KCNH2 (0.40) | SCN1ASCN8AKCNH2HRH3SLC2A1 | |
| SCHEMBL5527397 | 0.84 | HRH3 (0.52) | KCNH2HRH3SLC2A1RBP4TTR | |
| SCHEMBL5527506 | 0.83 | NCF1 (0.43) | SLC2A1POLBRBP4SCD | |
| SCHEMBL5529852 | 0.83 | HRH3 (0.40) | KCNH2HRH3SLC2A1RBP4TTR | |
| SCHEMBL14448782 | 0.80 | TTR (0.41) | KCNH2HRH3RBP4TTRSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | SCN1A 89/4885SCN8A 103/4885KCNH2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.